Oppenheimer lowered its price target on Biogen (NASDAQ: BIIB) to $375.00 (from $400.00) while maintaining a Outperform rating.Analyst Jay Olson ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Biogen (BIIB) PT Lowered to $272 at Cantor FitzgeraldApril 26, 2018 1:49 AM Biogen (BIIB) PT Lowered to $311 at RBC CapitalApril 25, 2018 7:43 AM Biogen (BIIB) PT Raised to $369 at Morgan StanleyApril 25, 2018 7:24 AM Biogen (BIIB) PT Lowered to $325 at Leerink PartnersApril 25, 2018 6:37 AM Biogen (BIIB) PT Lowered to $385 at GuggenheimApril 25, 2018 2:03 AM UPDATE: Baird Upgrades Biogen (BIIB) to OutperformApril 25, 2018 1:08 AM UPDATE: Goldman Sachs Downgrades Biogen (BIIB) to BuyApril 25, 2018 12:56 AM Form 10-Q BIOGEN INC. For: Mar 31April 24, 2018 4:55 PM Biogen (BIIB) PT Lowered to $353 at Piper JaffrayApril 24, 2018 1:30 PM Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q April 24, 2018 8:48 AM Biogen (BIIB) Tops Q1 EPS by 13c, Miss on RevenuesApril 24, 2018 7:00 AM Biogen Reports Quarterly Revenues of $3.1 BillionApril 24, 2018 6:59 AM